| 63.6 -1.5 (-2.3%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 81.86 | 1-year : | 88.89 |
| Resists | First : | 70.08 | Second : | 76.11 |
| Pivot price | 63.59  |
|||
| Supports | First : | 60.34 | Second : | 50.2 |
| MAs | MA(5) : | 64.08 |
MA(20) : | 63.51 |
| MA(100) : | 56.99 |
MA(250) : | 34.01 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 56.1 |
D(3) : | 59.6 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 76.76 | Low : | 9.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARWR ] has closed below upper band by 49.9%. Bollinger Bands are 72.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 65.79 - 66.11 | 66.11 - 66.37 |
| Low: | 62.63 - 63.07 | 63.07 - 63.42 |
| Close: | 62.99 - 63.65 | 63.65 - 64.18 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Wed, 04 Mar 2026
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Wed, 04 Mar 2026
Fisher Asset Management LLC Acquires 602,139 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Mon, 02 Mar 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Competitors - Meyka
Mon, 02 Mar 2026
ARWR: Key 2026 data readouts and strong FCS launch highlight a robust cardiometabolic and CNS pipeline - TradingView
Sun, 01 Mar 2026
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 140 (M) |
| Held by Insiders | 1.2203e+008 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 9,630 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.2565e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 18.5 % |
| Operating Margin | 15.4 % |
| Return on Assets (ttm) | 14.3 % |
| Return on Equity (ttm) | 75.5 % |
| Qtrly Rev. Growth | 10 % |
| Gross Profit (p.s.) | 378.11 |
| Sales Per Share | 8.93443e+008 |
| EBITDA (p.s.) | 8.93443e+008 |
| Qtrly Earnings Growth | 1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 339 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 18.74 |
| Dividend | 0 |
| Forward Dividend | 1.115e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|